NDA/BLA filedoutcome: unknownconf 0.95
adx-2191 — NDA/BLA filed
$ALDX · Aldeyra Therapeutics, Inc. · primary vitreoretinal lymphoma
Event date
March 2, 2023
1192 days ago
Sponsor runway
38 mo
$65.0M liquid
Evidence
Comparable historical nda/bla fileds· last 5 years · same event type
| Ticker | Drug | Date | Outcome |
|---|---|---|---|
| $AXSM | — | 2025-12-31 | unknown |
| $RCKT | kresladi | 2025-10-14 | unknown |
| $ALDX | reproxalap | 2025-07-17 | unknown |
| $ETON | et-600 | 2025-07-08 | unknown |
| $BCRX | orladeyo (berotralstat) | 2025-05-14 | unknown |
| $CORT | relacorilant | 2025-03-03 | unknown |
| $ALDX | reproxalap | 2024-11-01 | unknown |
| $AXSM | axs-07 | 2024-09-04 | unknown |
| $RCKT | kresladi | 2023-10-02 | unknown |
| $GERN | imetelstat | 2023-08-21 | unknown |
Recent insider activity· ±90 days
4 insiders · 1 buys · 0 sells
Buy
2023-04-12Miller-Rich Nancy
Director
509 @ $10.13$5K
Grant
2023-02-28Machatha Stephen
Chief Development Officer
220,258 @ ——
Grant
2023-02-28Greenberg Bruce
See Remarks
110,028 @ ——
Grant
2023-02-28Brady Todd C
President and CEO
238,750 @ ——
Grant
2023-02-28Brady Todd C
President and CEO
250,000 @ ——